Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FIA586 in Hepatic Impairment
NCT04993157Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FIA586 in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (3 arms), sponsored by Novartis. Primary endpoints: Maximum Observed Blood Concentrations at 120 hours, Area Under Plasma Concentration-time Curve from time zero to the last measurable concentration and 6 more. Started Dec 2021; status: completed.
02
Drugs
FIA586
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04993157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993157.